Form 4: Inmune Bio CEO Raymond Tesi Increases Stake in Company Through Direct Offering

Inmune Bio's CEO, Raymond Joseph Tesi, acquired 18,028 shares of common stock and warrants in a registered direct offering, increasing his beneficial ownership in the company.

Summary

• Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc., has increased his stake in the company.
• On April 19, 2024, Tesi acquired 18,028 shares of common stock at a price of $8.32 per share.
• He also acquired warrants to purchase 18,028 shares of common stock at an exercise price of $9.152 per share.
• These transactions were part of a registered direct offering with an aggregate purchase price of $152,246.46.
• Following these transactions, Tesi directly owns 1,538,726 shares of Inmune Bio's common stock.
• The warrants are exercisable immediately upon issuance and expire two years from the initial exercise date or 30 trading days after the reporting of top-line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, whichever is earlier, with a provision for blackout periods.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO increasing his stake in the company, which is generally seen as a good sign. However, it's important to consider the context of the direct offering and the specific terms of the warrants.

Positives

• The CEO's increased investment in the company may signal confidence in Inmune Bio's future prospects.
• The registered direct offering provides the company with additional capital.

Future Outlook

The warrants' exercisability is tied to the reporting of top-line data from the Phase 2 Alzheimer's program of XPro1595, suggesting that the CEO's investment strategy is linked to the clinical trial's progress.

Industry Context

Insider buying can be viewed positively by the market, especially when it comes from key executives like the CEO. It suggests a strong belief in the company's strategy and future performance, particularly in the competitive biotechnology sector.

Stakeholder Impact

• Shareholders may view the CEO's increased investment positively.
• The company's employees may feel more secure knowing the CEO has confidence in the company's future.

Next Steps

• The market will likely monitor the progress of the Phase 2 Alzheimer's program of XPro1595, as the warrants' exercisability is linked to its top-line data reporting.
• Investors may also watch for further insider transactions.

Key Dates